Catalyst Pharmaceuticals (CPRX) Tops Q2 EPS by 28c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
August 9, 2023 4:17 PM EDTAchieved Record Q2 2023 Total Net Revenues of $99.6 MillionAchieved FIRDAPSE® 2023 Second Quarter Net Revenues of $64.9 Million, a 22% Increase YOYAchieved 2023 Second Quarter GAAP EPS Diluted of $0.33 Compared to $0.20 for Q2 2022Achieved 2023 Second Quarter Non-GAAP EPS Diluted of $0.53 Compared to $0.28 for Q2 2022During Q3-23 Completed the Acquisition of the North American License for VamoroloneSubmitted sNDA for FIRDAPSE Seeking to Increase the Maximum Indicated Dose to 100 mg per DayCompleted the Integration of our FYCOMPA® Commercial and MSL TeamsRaising Full Year 2023 Total Revenue Guidance of Between $380 Million and $390 MillionConference... More
